zanamivir ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals neuraminidase inhibitors 2859 139110-80-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zanamivir
  • relenza
  • zanamivir hydrate
A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.
  • Molecular weight: 332.31
  • Formula: C12H20N4O7
  • CLOGP: -5.56
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 8
  • TPSA: 198.22
  • ALOGS: -2.35
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg Inhal.powder
1.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 36 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 100 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.86 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 2 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.86 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 37
kinase-selectivity-class AXL,CDK9,GRK2,MAP2K6,MAP3K14,TEK,TGFBR1 7
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
April 26, 2019 EMA GlaxoSmithKline Trading Services Limited
July 26, 1999 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pathogen resistance 55.52 49.15 14 608 17658 110571019

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AH01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Neuraminidase inhibitors
FDA MoA N0000175436 Neuraminidase Inhibitors
FDA EPC N0000175524 Neuraminidase Inhibitor
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:52425 EC 3.2.1.18 (<i>exo</i>-ฮฑ-sialidase) inhibitor

Related Drugs by ATC class:

J05AH Neuraminidase inhibitors 3 drugs
laninamivir octanoate hydrateoseltamivirperamivir

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469
Delirium contraindication 2776000
Bronchospasm contraindication 4386001
Hallucinations contraindication 7011001
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Feeling agitated contraindication 24199005
Seizure disorder contraindication 128613002
Impaired cognition contraindication 386806002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.46 acidic
pKa2 12.0 acidic
pKa3 13.81 acidic
pKa4 13.85 acidic
pKa5 9.82 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sialidase 3 Enzyme IC50 5.17 CHEMBL
Sialidase 2 Enzyme Ki 4.77 CHEMBL
Sialidase-4 Enzyme Ki 4.58 CHEMBL
Neuraminidase Enzyme INHIBITOR IC50 9.30 CHEMBL CHEMBL
Neuraminidase Enzyme INHIBITOR Ki 10 CHEMBL CHEMBL
Neuraminidase Enzyme IC50 8.58 CHEMBL
Neuraminidase Enzyme Ki 9.30 CHEMBL
Neuraminidase Enzyme Ki 9 CHEMBL
Neuraminidase Enzyme Ki 9.40 CHEMBL
Neuraminidase Enzyme Ki 9.30 CHEMBL
Neuraminidase Enzyme IC50 7.64 CHEMBL
Neuraminidase Enzyme IC50 8.54 CHEMBL
Neuraminidase Enzyme IC50 5.85 CHEMBL
Neuraminidase Enzyme IC50 8.13 CHEMBL
Neuraminidase Enzyme IC50 8.05 CHEMBL
Neuraminidase Enzyme IC50 8.47 CHEMBL
Neuraminidase Enzyme IC50 8.76 CHEMBL
Neuraminidase Enzyme IC50 7.64 CHEMBL
Neuraminidase Enzyme IC50 8.40 WOMBAT-PK
Neuraminidase Enzyme Kd 8.33 CHEMBL
Neuraminidase Enzyme IC50 8.62 CHEMBL

External reference:

IDSource
4021167 VUID
N0000148618 NUI
D00902 KEGG_DRUG
4021167 VANDF
C0216660 UMLSCUI
CHEBI:50663 CHEBI
ZMR PDB_CHEM_ID
CHEMBL222813 ChEMBL_ID
DB00558 DRUGBANK_ID
CHEMBL5315117 ChEMBL_ID
D053243 MESH_DESCRIPTOR_UI
60855 PUBCHEM_CID
12307 IUPHAR_LIGAND_ID
7272 INN_ID
551942-41-7 SECONDARY_CAS_RN
L6O3XI777I UNII
261633 RXNORM
31156 MMSL
8261 MMSL
d04443 MMSL
007857 NDDF
116100000 SNOMEDCT_US
1217563005 SNOMEDCT_US
387010007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 0173-0681 POWDER 5 mg RESPIRATORY (INHALATION) NDA 26 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 50090-8016 POWDER 5 mg RESPIRATORY (INHALATION) NDA 26 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 54868-4377 POWDER 5 mg RESPIRATORY (INHALATION) NDA 25 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 68258-3030 POWDER 5 mg RESPIRATORY (INHALATION) NDA 25 sections